Next Virtual Grand Rounds on Mar. 12 to look at the promises and pitfalls of new weight loss drugs

March 06, 2024
Area(s) of Interest: Professional Development & Education 

Obesity management began to shift dramatically starting in 2014 with the first FDA approval of a GLP-1 receptor agonist (RA) for weight loss. But things really took off in 2021 with the approval of another medication to this class, semaglutide.

Join us for the next installment of CMA’s Virtual Grand Rounds—Virtual Grand Rounds: New Weight Loss Medications - Panacea or Pandora's Box—on Tuesday, March 12, 2024, at 12:00 p.m, to hear from experts about the evidence and real-world data on this new class of obesity medications.

And as always, we will hear from California State Epidemiologist Erica Pan, M.D., MPH, who will review the current status of COVID-19, influenza and other winter respiratory viruses.

The free one-hour webinar is open to all interested parties.   

Virtual Grand Rounds: Emerging Public Health Issues is a free and monthly series providing the latest patient management news and resources. The effort is a partnership between CMA and the California Health and Human Services Agency, with the California Academy of Physician Assistants and the Osteopathic Physicians and Surgeons of California.

If you are unable to attend the live event, it will be available for on-demand playback at cmadocs.org/grandrounds.



Was this article helpful?    
Download the New CMADocs app!

Download the new CMADocs app!

CMA's new mobile app lets you connect with your colleagues and engage with CMA content!  Download the "CMADocs" app today from the Apple or Google Play app stores for daily news updates, events calendar, resource library and more.

Latest News

Load More